Author name: TB Alliance

World Health Organization (WHO): “Priority Medicines for Europe and the World” This report, launched at the conference on “Priority Medicines

After three and a half years of dedicated service as the Director of Advocacy and Public Affairs at the TB

IN MEMORIAMJohn R. La Montagne, Ph.D.,NIAID Deputy DirectorSecretary, TB Alliance Board of Directors1943 – 2004 Dr. John La Montagne, deputy

[SINGAPORE] The Novartis Institute for Tropical Diseases (NITD) and the Global Alliance for Tuberculosis Drug Development (TB Alliance) have announced

Tuberculosis (TB) is the world’s oldest known infectious disease and the one that kills the most people today, about two

The Global Alliance for TB Drug Development plans to team up with a unit of Novartis AG to speed development

Policy discussions on new drugs and R&D have taken on new urgency because of recent policy papers and upcoming key

The TB Alliance is teaming up with researchers at the University of Illinois at Chicago (UIC) College of Pharmacy to

A class of drug, which is currently used to fight respiratory tract infections, has demonstrated pharmacological features and potential antibacterial